Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Cash from Operations (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Cash from Operations for 10 consecutive years, with 3220000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 33.08% to 3220000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 19361000.0 through Dec 2025, up 13.14% year-over-year, with the annual reading at 19361000.0 for FY2025, 13.14% up from the prior year.
  • Cash from Operations for Q4 2025 was 3220000.0 at Rein Therapeutics, up from 3548000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 1640000.0 in Q3 2023, with the low at 10391000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 5503950.0, with a median of 5478000.0 recorded in 2022.
  • The sharpest move saw Cash from Operations soared 76.47% in 2023, then crashed 169.22% in 2024.
  • Over 5 years, Cash from Operations stood at 6255000.0 in 2021, then grew by 29.51% to 4409000.0 in 2022, then tumbled by 135.68% to 10391000.0 in 2023, then skyrocketed by 53.69% to 4812000.0 in 2024, then skyrocketed by 33.08% to 3220000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 3220000.0, 3548000.0, and 6418000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.